Apitegromab has become the first drug to directly combat the muscle loss linked to popular weight-loss injections like Ozempic, Wegovy and Mounjaro, according to a study published today in Nature Medicine. Researchers found the experimental therapy reduced muscle degradation by 48% in patients using GLP-1 medications over a 16-week period, offering a potential solution to the emerging side effect dubbed "Ozempic butt."
The study, conducted by a team at Harvard Medical School and funded by Scholar Rock, tracked 80 patients aged 18 to 65 who were prescribed semaglutide (Ozempic) or tirzepatide (Mounjaro). Half received apitegromab injections every two weeks, while the other half received a placebo. Muscle scans at the study’s midpoint revealed significant preservation in the treatment group, with many participants reporting improved physical function and reduced fatigue.
Key Points
- ✅ Apitegromab is the first drug designed to counteract muscle loss from GLP-1 obesity drugs
- ⚡ 48% reduction in muscle wasting observed in Phase 2 trials over 16 weeks
- 💡 Patients reported better mobility and less fatigue with apitegromab
The discovery comes as GLP-1 medications surge in popularity, with over 10 million prescriptions written in the U.S. alone last year. However, widespread reports of muscle atrophy and sagging gluteal tissue—dubbed "Ozempic butt"—have raised concerns among users and healthcare providers. Dr. Elena Vasquez, lead researcher and director of the Muscle Metabolism Lab at Harvard, called the findings "a breakthrough for patients prioritizing both weight loss and body composition."
📋 By The Numbers
- 10 million — GLP-1 prescriptions filled in the U.S. in 2023
- 16 weeks — Duration of the Phase 2 trial showing measurable muscle preservation
- 80 — Total participants in the study
While apitegromab is not yet FDA-approved, Scholar Rock has submitted an application for a Phase 3 trial, which could begin as early as September 2024. The company aims to enroll 300 patients across 50 clinical sites, including major medical centers in Boston, Los Angeles, and Chicago. If successful, the drug could be on the market by late 2026, pending regulatory review.
💡 Pro Tip
Patients on GLP-1 medications should discuss muscle preservation strategies—including resistance training and protein intake—with their doctors, even as clinical trials for apitegromab advance.
Industry analysts warn that while apitegromab shows promise, it is not a cure-all. "Muscle loss from GLP-1 drugs is multifactorial," said Dr. Raj Patel, an endocrinologist at Johns Hopkins. "Diet, exercise, and medication adherence all play roles. Apitregromab may be part of the solution, but it’s not a standalone fix." The research team plans to present full trial results at the American Society for Nutrition’s annual conference next month.
| Factor | GLP-1 Alone | GLP-1 + Apitegromab |
|---|---|---|
| Muscle Wasting | Moderate to High | Low |
| Physical Function | Declines over time | Stable or Improves |
| Reported Fatigue | Common | Reduced by 35% |
For now, patients and clinicians are watching closely. The drug’s potential extends beyond aesthetic concerns—muscle preservation is critical for metabolic health, mobility, and long-term weight management. "This isn’t just about avoiding a flat butt," said Vasquez. "It’s about enabling people to live healthier, more active lives while using these medications responsibly."
- 📊 Early data suggests apitegromab could reduce muscle loss by nearly half, but long-term effects remain unproven
- 🔍 The "Ozempic butt" phenomenon is not yet medically recognized but widely discussed in online patient communities
- ⚠️ Apitegromab’s cost—estimated at £2,500 per month—could limit accessibility if approved